Solara Active Pharma Sciences Limited (SOLARA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Solara Active Pharma Sciences Limited (SOLARA) has a cash flow conversion efficiency ratio of 0.059x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs740.70 Million ≈ $8.01 Million USD) by net assets (Rs12.57 Billion ≈ $135.99 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Solara Active Pharma Sciences Limited - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Solara Active Pharma Sciences Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Solara Active Pharma Sciences Limited total liabilities for a breakdown of total debt and financial obligations.
Solara Active Pharma Sciences Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Solara Active Pharma Sciences Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Polaris Infrastructure Inc
TO:PIF
|
0.052x |
|
Anterogen.Co.Ltd
KQ:065660
|
0.003x |
|
Dynamic Cables Limited
NSE:DYCL
|
0.012x |
|
AgriFORCE Growing Systems Ltd
NASDAQ:AGRI
|
-0.196x |
|
Michlol Finance Ltd
TA:MCLL
|
-0.410x |
|
Greenx Metals Ltd
AU:GRX
|
-0.223x |
|
India Nippon Electricals Limited
NSE:INDNIPPON
|
0.001x |
|
Saksoft Limited
NSE:SAKSOFT
|
0.099x |
Annual Cash Flow Conversion Efficiency for Solara Active Pharma Sciences Limited (2017–2025)
The table below shows the annual cash flow conversion efficiency of Solara Active Pharma Sciences Limited from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see Solara Active Pharma Sciences Limited (SOLARA) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | Rs10.97 Billion ≈ $118.63 Million |
Rs2.13 Billion ≈ $23.02 Million |
0.194x | +66.91% |
| 2024-03-31 | Rs9.37 Billion ≈ $101.29 Million |
Rs1.09 Billion ≈ $11.77 Million |
0.116x | +11.78% |
| 2023-03-31 | Rs15.02 Billion ≈ $162.49 Million |
Rs1.56 Billion ≈ $16.90 Million |
0.104x | +165.95% |
| 2022-03-31 | Rs15.35 Billion ≈ $165.98 Million |
Rs-2.42 Billion ≈ $-26.17 Million |
-0.158x | -261.57% |
| 2021-03-31 | Rs15.93 Billion ≈ $172.25 Million |
Rs1.55 Billion ≈ $16.81 Million |
0.098x | -56.43% |
| 2020-03-31 | Rs10.90 Billion ≈ $117.90 Million |
Rs2.44 Billion ≈ $26.41 Million |
0.224x | +34.55% |
| 2019-03-31 | Rs9.60 Billion ≈ $103.85 Million |
Rs1.60 Billion ≈ $17.29 Million |
0.166x | +159.91% |
| 2018-03-31 | Rs7.68 Billion ≈ $83.11 Million |
Rs492.23 Million ≈ $5.32 Million |
0.064x | -100.00% |
| 2017-03-31 | Rs67.00K ≈ $724.58 |
Rs492.23 Million ≈ $5.32 Million |
7346.716x | -- |
About Solara Active Pharma Sciences Limited
Solara Active Pharma Sciences Limited manufactures, produces, processes, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India, Asia Pacific, Europe, North America, South America, and internationally. The company offers APIs for amyotrophic lateral sclerosis, anesthetics, anthelmintic, anti hyperlipidemic, anti-arr… Read more